Sinovac Biotech Ltd. (SVA) Stock Score, Valuation & Financial Research
Sinovac Biotech Ltd. is in the Healthcare sector and Medical - Pharmaceuticals industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 30/100.
Quick answer for SVA
Sinovac Biotech Ltd. currently has a Wall Street Score of 30/100. The stored market price is $6.47. Its financial score is 25/100. Its valuation score is 4/100. These figures are a research snapshot, not a buy or sell recommendation.
What Sinovac Biotech Ltd. does
Sinovac Biotech Ltd. is a biopharmaceutical firm primarily dedicated to the discovery, research, manufacturing, and sales of vaccines aimed at combating infectious human diseases across the People's Republic of China. Its extensive product range encompasses immunizations against Hepatitis A and B; hand, foot, and mouth disease caused by Enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza strains; coronavirus; varicella (chickenpox); and mumps. Among its commercially available vaccines are Healive, an inactivated Hepatitis A vaccine; Bilive, offering combined inactivated protection for Hepatitis A and B; Anflu, a split-virion influenza vaccine; Panflu, targeting the H5N1 influenza virus; Panflu.1, for the influenza A H1N1 virus; a mumps vaccine; another split-virion pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company further supplies a varicella va
SVA financial snapshot
- Wall Street Score:
- 30/100
- Current price:
- $6.47
- Market capitalization:
- $464.9M
- Revenue:
- $1.94B
- Net income:
- $13.9M
- Free cash flow:
- $-559.4M
- Cash:
- $488.2M
- Total debt:
- $505.6M
- EPS:
- 0.14
- P/E ratio:
- 46.2x
- Financial score:
- 25/100
- Valuation score:
- 4/100
- Revenue score:
- 43/100
What stands out
- Reported year-over-year revenue growth is +4.0%.
- Free cash flow is $-559.4M, showing cash burn in the current stored period.
- The balance sheet shows $488.2M of cash versus $505.6M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 4/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research SVA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.